{"entity":{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","aka":[],"tldr":"Showed that whole-exome sequencing of blood can track how a cancer evolves, and co-founded Inivata.","summary":"Nitzan Rosenfeld led the 2013 Nature study showing that exome sequencing of circulating tumour DNA tracks the evolution of resistance across multiple cancers, and the earlier work using tagged-amplicon sequencing to monitor breast cancer, both foundational to liquid biopsy. He developed methods for detecting ctDNA at very low fractions and co-founded Inivata, now part of NeoGenomics. He moved from Cambridge to Barts in 2023.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenfeld%20N%5BAuthor%5D%20circulating%20tumor%20DNA"}],"tags":["ctdna","liquid-biopsy","genomics"],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy","mrd-testing","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["barts-cancer-institute","cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Cancer Genomics, Barts Cancer Institute; former Senior Group Leader, CRUK Cambridge Institute","institutionId":"barts-cancer-institute","specialisms":["Circulating tumour DNA","Liquid biopsy methods","Cancer genomics","Early detection"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Rosenfeld%20N%5BAuthor%5D%20circulating%20tumor%20DNA"}],"papers":[{"title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","journal":"Nature","year":2013,"doi":"10.1038/nature12065"},{"title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1213261"}]},"route":"/people/nitzan-rosenfeld/","neighbours":{"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"institution":[{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/"},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}]}}